Benítez-Herreros J, Pérez-Rico C, Teus M A, Gómez-San Gil Y, Castro-Rebollo M
Servicio de Oftalmología, Hospital Universitario Príncipe de Asturias, Universidad de Alcalá, Madrid, España.
Arch Soc Esp Oftalmol. 2010 Oct;85(10):329-32. doi: 10.1016/j.oftal.2010.09.011. Epub 2010 Nov 3.
To determine the effect of intravitreal injection of 0.5mg ranibizumab on the corneal endothelium in patients with age-related macular degeneration (AMD).
Observational, prospective case series pilot study. Twenty-six eyes of 26 consecutive patients with AMD were evaluated. All participants received one monthly intravitreal injections of 0.5mg ranibizumab for three consecutive months. The follow-up period was 6 months. Central corneal specular microscopy was performed before injection and at 7 days and 6 months after the first intravitreal injection. The endothelial cell density, coefficient of variation of cell size, and percentage of hexagonal cells were analyzed and the central corneal thickness was measured.
There were no significant differences in the endothelial cell densities, coefficients of variation of cell size and percentages of hexagonal cells before injection and at 7 days and 6 months after the first intravitreal ranibizumab injection (P>0.5). There was also no significant difference in central corneal thickness measurements through the follow-up period (P>0.5).
Repeated intravitreal injections of 0.5mg ranibizumab do not seem to cause substantial changes in the corneal endothelium.
确定玻璃体内注射0.5毫克雷珠单抗对年龄相关性黄斑变性（AMD）患者角膜内皮的影响。
观察性、前瞻性病例系列试点研究。对连续26例AMD患者的26只眼进行评估。所有参与者连续三个月每月接受一次0.5毫克雷珠单抗玻璃体内注射。随访期为6个月。在注射前以及首次玻璃体内注射后7天和6个月进行中央角膜内皮显微镜检查。分析内皮细胞密度、细胞大小变异系数和六边形细胞百分比，并测量中央角膜厚度。
在注射前以及首次玻璃体内注射雷珠单抗后7天和6个月，内皮细胞密度、细胞大小变异系数和六边形细胞百分比均无显著差异（P>0.5）。在整个随访期间，中央角膜厚度测量也无显著差异（P>0.5）。
重复玻璃体内注射0.5毫克雷珠单抗似乎不会引起角膜内皮的实质性变化。
